Investigating why some patients with chronic lymphocytic leukemia resist treatment with BTK inhibitors
Official title: Understanding mechanisms of BTK inhibitor and degrader resistance in patients with chronic lymphocytic leukemia
Funded at University of Miami School of Medicine · NIH-10943869 · Data updated 2026-11-12
This study is looking into why some people with chronic lymphocytic leukemia (CLL) don’t respond to certain medications called BTK inhibitors, with the goal of finding better treatment options for those who struggle with these therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $351,131 |
| NIH project number | 1R01CA292653-01 |
| Project ID | NIH-10943869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with chronic lymphocytic leukemia who have experienced resistance or intolerance to BTK inhibitors.
✕Less likely to help
Patients who do not have chronic lymphocytic leukemia or those who have not been treated with BTK inhibitors may not benefit from this research.
What this research studies
This research focuses on understanding why some patients with chronic lymphocytic leukemia (CLL) do not respond to BTK inhibitors, which are designed to treat B-cell malignancies. The team will explore the molecular mechanisms behind resistance to these treatments, including studying specific mutations in the BTK gene and other related pathways. By identifying these resistance mechanisms, the researchers aim to develop better treatment strategies that could include new drug combinations. This work is crucial for improving outcomes for patients who experience treatment failure.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with chronic lymphocytic leukemia who currently struggle with resistance to existing therapies.
How similar studies have gone: Previous research has shown promise in understanding resistance mechanisms in cancer therapies, making this approach both relevant and potentially impactful.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Taylor, Justin — University of Miami School of Medicine
- Study coordinator: Taylor, Justin
Related research
Other NIH-funded projects on the same topics.
-
Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome
A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.
-
Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults
A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.
-
AVO: a new triplet therapy for untreated high-risk CLL
A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.
-
Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia
A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.
-
METTL3's role in driving a stubborn form of chronic lymphocytic leukemia
A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.
-
Understanding why BTK inhibitors stop working in chronic lymphocytic leukemia
Researchers are studying why some people with chronic lymphocytic leukemia stop benefiting from BTK inhibitors and how to overcome that resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.